Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Lyell Immunopharma, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 52 | 62 | +10 |
| Shares | 79.7M | 82.5M | +2.83M (+3.6%) |
| Value | $1.29B | $1.22B | −$72.7M (−5.6%) |
New holders (28)
Institutions that held Lyell Immunopharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (18)
Institutions that held Lyell Immunopharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Arena Capital Advisors, LLC- CA | 545,137 | $8.85M |
| Goldman Sachs Group Inc | 202,034 | $3.28M |
| Monashee Investment Management LLC | 160,000 | $2.60M |
| Alliancebernstein L.P. | 100,000 | $1.62M |
| LMR Partners LLP | 85,000 | $1.38M |
| Pinz Capital Management, LP | 84,383 | $1.37M |
| Squarepoint Ops LLC | 50,987 | $828.0K |
| Qube Research & Technologies Ltd | 45,505 | $739.0K |
| Davidson Kempner Capital Management LP | 42,718 | $691.0K |
| Gsa Capital Partners LLP | 30,500 | $495.0K |
| Point72 Hong Kong Ltd | 28,407 | $461.0K |
| Point72 Asset Management, L.P. | 25,000 | $406.0K |
| ExodusPoint Capital Management, LP | 20,697 | $336.0K |
| Maven Securities LTD | 12,195 | $197.0K |
| Tudor Investment Corp Et Al | 11,954 | $194.0K |
| Rokos Capital Management LLP | 5,000 | $81.0K |
| Kirkoswald Asset Management LLC | 1,000 | $16.0K |
| Westchester Capital Management, LLC | 500 | $8.00K |